Burning Rock Biotech (BNR) Q2 2025 earnings summary

Executive summary

• Total revenues for Q2 2025 reached RMB148.5 million ($20.7 million), up 9.6% year-over-year, driven by growth in in-hospital and pharma R&D channels.

• Net loss narrowed significantly to RMB9.7 million ($1.4 million) from RMB108.0 million in Q2 2024.

• Operating expenses dropped 42.1% year-over-year due to budget controls and headcount reduction.

Financial highlights

• In-hospital business revenue grew 4.4% year-over-year to RMB62.5 million, while pharma R&D revenue surged 68.1% to RMB45.2 million.

• Central laboratory revenue declined 16.2% year-over-year to RMB40.9 million, reflecting a strategic shift to in-hospital testing.

• Gross profit increased 13.3% year-over-year to RMB108.1 million, with gross margin rising to 72.8% from 70.4%.

• Non-GAAP gross profit was RMB110.5 million, up 8.4% year-over-year; non-GAAP gross margin was 74.4%.

• Cash, cash equivalents, and restricted cash stood at RMB455.0 million ($63.5 million) as of June 30, 2025.

Outlook and guidance

• Management highlights ongoing transition to in-hospital testing and continued cost optimization.

• Forward-looking statements note risks and uncertainties due to market and operating conditions.